Prevention and treatment of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats

Ophthalmic Research

Volumn 42, Issue 2, 2009, Pages 90-95

  Hashemian, Mohammad Naser ^a   Moghimi, Sasan ^a   Kiumehr, Saman ^a   Riazi, Mohammad ^a,b   Amoli, Fahime Asadi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NOOR EYE HOSPITAL   (Iran)

Author keywords

Betamethasone; Bevacizumab; Chemical cauterization; Corneal neovascularization; Subconjunctival injection

Indexed keywords

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE; BEVACIZUMAB; POTASSIUM NITRATE; SILVER NITRATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUTERIZATION; CHEMICAL INJURY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL RAT; MALE; NONHUMAN; OCULAR BLOOD VESSEL; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SPRAGUE DAWLEY RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BETAMETHASONE; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; INJECTIONS; MALE; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67449141559     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224783     Document Type: Article

References (41)

1. Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-249.
2. Lee P, Wang CC, Adamis AP: Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-269.
3. Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, Cohen EJ: Corneal neovascularization after penetrating keratoplasty. Cornea 1995;14:604-609.
4. Wilson SE, Mohan RR, Mohan RR, Ambrosio R Jr, Hong J, Lee J: The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001;20:625-637. (Pubitemid 32695343)
5. Dana MR, Streilein JW: Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996;37:2485-2494.
6. Phillips GD, Stone AM, Jones BD, Schultz JC, Whitehead RA, Knighton DR: Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1994;8:961-965.
7. Gan L, Fagerholm P, Palmblad J: Vascular endothelium growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557-563. (Pubitemid 39386968)
8. Philipp W, Speicher L, Humpel C: Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-2522. (Pubitemid 30624378)
9. Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118. (Pubitemid 40365933)
10. Azar DT: Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264-302.
11. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA: Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431.
12. Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45:2666-2673. (Pubitemid 38998863)
13. Riazi-Esfahani M, Peyman GA, Aydin E, Kazi AA, Kivilcim M, Sanders DR: Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea 2006;25:801-805. (Pubitemid 44657255)
14. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
15. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799. (Pubitemid 46224178)
16. Yang JC, Haworth RM, Sherry RM, et al: A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
17. Avery RL, Pieramici DJ, Rabena MD, et al: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
18. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:e1-e12. (Pubitemid 44642322)
19. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN: Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9. (Pubitemid 43946791)
20. Avery RL: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354. (Pubitemid 44318195)
21. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P: Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807. (Pubitemid 46846656)
22. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C: Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545-2552. (Pubitemid 351261204)
23. Barros LF, Belfort R Jr: The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79:389-394.
24. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F: Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007;35:745-748. (Pubitemid 350090533)
25. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI: The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-e38.
26. Lipman RM, Epstein RJ, Hendricks RL: Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992;110:405-407.
27. Joussen AM, Kruse FE, Völcker HE, Kirchhof B: Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 1999;237:920-927.
28. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
29. Murata N, Yamaji T, Uchida M, Tsuboi H, Suzuki H, Yamada M, Oikawa T, Nobuhiro J, Choshi T, Hibino S: Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha- fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats. Biol Pharm Bull 2006;29:2410-2414. (Pubitemid 44885860)
30. Lemus D, Dabancens A, Illanes J, Fuenzalida M, Guerrero A, López C: Antiangiogenic effect of betamethasone on the chick cam stimulated by TA3 tumor supernatant. Biol Res 2001;34:227-236. (Pubitemid 33064686)
31. DeStafeno JJ, Kim T: Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125:834-836. (Pubitemid 46919748)
32. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP: Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22. (Pubitemid 28040457)
33. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT: Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001;75:9828-9835. (Pubitemid 32900118)
34. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY, Ansari AM, Scaria PV, Woodle MC, Lu P, Rouse BT: Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004;165:2177-2185. (Pubitemid 39578394)
35. D'Amore PA: Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994;35:3974-3979.
36. Binétruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouët J, Derbin C, Perret G, MaziéJC: Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000;19:1525-1533. (Pubitemid 30182160)
37. 1 in human corneas with neovascularisation. Cornea 2000;19:526-533.
38. Noue K, Amano S, Oshika T, Tsuru T: Risk factors for corneal graft failure and rejection in penetrating keratoplasty. Acta Ophthalmol Scand 2001;79:251-255. (Pubitemid 32577308)
39. Price MO, Thompson RW Jr, Price FW Jr: Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol 2003;121:1087-1092.
40. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.
41. Kim TI, Kim SW, Kim S, Kim T, Kim EK: Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349-352.